NCT02724865

Brief Summary

Obstructive sleep apnea (OSA) is a common chronic sleep disorder that often requires lifelong care. The prevalence in the Netherlands is estimated around 300.000 patients. Due to longer life expectancy and increase in weight in the general population, its prevalence is expected to rise. Patients with mild and moderate OSA are treated primarily with an oral appliance at present time. Different oral appliances are available, but most used is the mandibular advancement device (MAD). This study focuses on two different types of MAD: the classic Herbst appliance, which is attached to the mandible and the maxilla and has an iron bar to regulate the open space; and the Somnodent, which consists of two separate splints, fixed on the mandible and the maxilla, but has no iron bar attached.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
140

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2016

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 14, 2016

Completed
17 days until next milestone

First Posted

Study publicly available on registry

March 31, 2016

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

April 13, 2016

Status Verified

April 1, 2016

Enrollment Period

2.3 years

First QC Date

March 14, 2016

Last Update Submit

April 12, 2016

Conditions

Keywords

Oral Appliance Therapy

Outcome Measures

Primary Outcomes (2)

  • Apnea-hypnea-Index (AHI)

    AHI is measured with polysomnography in hospital

    12 months

  • Oxygen-desaturation-Index

    ODI is measured with polysomnography in hospital

    12 months

Secondary Outcomes (4)

  • Epworth Sleeping Scale

    12 months

  • Functional Outcome of Sleep Questionnaire

    12 months

  • Blood pressure

    12 months

  • Euroqol (EQ-5D-3L)

    12 months

Other Outcomes (1)

  • Heart Rate

    12 months

Study Arms (2)

Oral appliance therapy; Somnodent®

ACTIVE COMPARATOR

Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.

Device: Somnodent® (Oral appliance therapy)

Oral appliance therapy; Herbst®

ACTIVE COMPARATOR

Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.

Device: Herbst® (Oral appliance therapy)

Interventions

Oral appliance therapy; Somnodent®
Oral appliance therapy; Herbst®

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years and older
  • Ability to speak, read, and write Dutch.
  • Ability to follow-up.
  • Ability to use a computer with internet connection for online questionnaires.
  • Diagnosis with symptomatic mild or moderate OSA (5 \< AHI \< 30).
  • Expected to maintain current lifestyle (sports, medicine, diet, etc.)

You may not qualify if:

  • Untreated periodontal problems, dental pain, and a lack of retention possibilities for an MAD.
  • Medication used/related to sleeping disorders.
  • Evidence of respiratory/sleep disorders other than OSA (eg. central sleep apnea syndrome).
  • Systemic disorders (based on medical history and examination; e.g. rheumatoid arthritis)
  • Temporomandibular disorders (based on the function examination of the masticatory system).
  • Medical history of known causes of tiredness by day, or severe sleep disruption (insomnia, Periodic Limb Movement Disorder, Narcolepsy).
  • Known medical history of mental retardation, memory disorders, or psychiatric disorders.
  • Reversible morphological upper airway abnormalities (e.g. enlarged tonsils). - Inability to provide informed consent.
  • simultaneous use of other modalities to treat OSA.
  • Previous treatment with a MAD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Academic Medical Center Amsterdam

Amsterdam, 1105 AZ, Netherlands

RECRUITING

Related Publications (4)

  • Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65 Suppl 16:12-6.

    PMID: 15575799BACKGROUND
  • Hoekema A, Stegenga B, De Bont LG. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med. 2004 Jun 4;15(3):137-55. doi: 10.1177/154411130401500303.

  • Shi X, Lobbezoo F, Chen H, Rosenmoller BRAM, Berkhout E, de Lange J, Aarab G. Effects of mandibular advancement devices on upper airway dimensions in obstructive sleep apnea: responders versus non-responders. Clin Oral Investig. 2023 Sep;27(9):5649-5660. doi: 10.1007/s00784-023-05186-w. Epub 2023 Aug 17.

  • Shi X, Lobbezoo F, Chen H, Rosenmoller BRAM, Berkhout E, de Lange J, Aarab G. Comparisons of the effects of two types of titratable mandibular advancement devices on respiratory parameters and upper airway dimensions in patients with obstructive sleep apnea: a randomized controlled trial. Clin Oral Investig. 2023 May;27(5):2013-2025. doi: 10.1007/s00784-023-04945-z. Epub 2023 Mar 17.

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Central Study Contacts

Maurits de Ruiter, DDS

CONTACT

Jan de Lange, MD, DDS, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 14, 2016

First Posted

March 31, 2016

Study Start

January 1, 2016

Primary Completion

May 1, 2018

Study Completion

July 1, 2018

Last Updated

April 13, 2016

Record last verified: 2016-04

Locations